#Montreal cognitive assessment test moca full version#

The exclusion criterion for the MCI group was a diagnosis of dementia. The inclusion criteria of the MCI group were: age ≥65 years education ≥4 years a subjective cognitive complaint, preferably confirmed by an informant an objective cognitive deficit confirmed by a low performance under the level expected on neuropsychological tests normal general cognitive functions and intact or minimally impaired functional activities. The exclusion criteria for the control group were: a diagnosis of dementia a diagnosis of relevant neurological or psychiatric diseases or systematic uncontrolled chronic diseases that have an impact on cognition a history of alcoholism or substance abuse aphasia or a visual, hearing, or motor handicap evidence of loss of autonomy or independence in daily activities regular use of psychotropic drugs and altered performance on neuropsychological tests. MoCA is among the top innovations in Alzheimer’s research in Canada, according to Canadian Institute of Health Research (2013).The inclusion criteria for the control group were: age ≥65 years and education ≥4 years. MoCA is used in 200+ countries around the world. JAGS 2005) is identified by Thomson Reuters’ Essential Science Indicators as one of the most cited papers in the research area of “mild cognitive Impairment”. The MoCA validation study (Nasreddine et al. The MoCA is recommended by the Canadian Consensus Conference for Diagnosis and Treatment of Dementia Guidelines for Alzheimer’s disease since 2007, and the NIH and Canadian Stroke Consortium for Vascular Cognitive Impairment since 2006.

#Montreal cognitive assessment test moca full version#

The latest full version of the test is now available on an iPad. The full test has also been adapted for people with disabilities including both physical and mental. To decrease the learning effect from multiple administrations of the MoCA over a short period of time, alternate versions have been made available. (A language validation study was conducted for many languages to demonstrate the validity of the test in the newly translated language.)

The test is available in nearly 200 countries, and many centers around the world are authorized to translate, adapt, and validate the test for their specific linguistic, cultural, and educational differences. In 2003, after analysis of the 2000 study results, a few elements of the test were optmized, and a new validation study was completed in 2003-2004, which confirmed the test’s discriminatory ability to distinguish Normal controls, from subjects with Mild Cognitive Impairment or Mild Alzheimer’s disease. MoCA performance to distinguish the two groups was excellent. All subjects were classified as cognitively intact or impaired based on a gold standard neuropsychological assessment. MoCA is the most sensitive test available for detecting Alzheimer’s disease, measuring executive functions and multiple cognitive domains which are important components not measured by the MMSE.įrom 1992 to 2000, MoCA went through many versions and adaptations before it was first validated in 2000 on a consecutive group of subjects that were referred to a memory clinic. The Montreal Cognitive Assessment (MoCA) is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care.